Active Biotech: Active Biotech : Interview with Prof. Dr. Axel Glasmacher, Independent Board Member at Active Biotech

(marketscreener.com) In collaboration with academic centers in the US and Europe, Active Biotech is about to start two clinical proof-of-concept studies with tasquinimod in Myelofibrosis, a rare blood cancer with high unmet medical need. We discussed with Prof. Glasmacher regarding his views on the biotech sector at present, his experience from working...https://www.marketscreener.com/quote/stock/ACTIVE-BIOTECH-AB-6491412/news/Active-Biotech-Interview-with-Prof-Dr-Axel-Glasmacher-Independent-Board-Member-at-Active-Biotec-46707771/?utm_medium=RSS&utm_content=20240513